APA (7th ed.) Citation

Zhu, C., Li, H., Yang, X., Wang, S., Wang, Y., Zhang, N., . . . Zhao, H. (2023). Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma. Cancer Immunology, Immunotherapy, 72(9), 2949-2960. https://doi.org/10.1007/s00262-023-03466-8

Chicago Style (17th ed.) Citation

Zhu, Chengpei, et al. "Efficacy, Safety, and Prognostic Factors of PD-1 Inhibitors Combined with Lenvatinib and Gemox Chemotherapy as First-line Treatment in Advanced Intrahepatic Cholangiocarcinoma." Cancer Immunology, Immunotherapy 72, no. 9 (2023): 2949-2960. https://doi.org/10.1007/s00262-023-03466-8.

MLA (9th ed.) Citation

Zhu, Chengpei, et al. "Efficacy, Safety, and Prognostic Factors of PD-1 Inhibitors Combined with Lenvatinib and Gemox Chemotherapy as First-line Treatment in Advanced Intrahepatic Cholangiocarcinoma." Cancer Immunology, Immunotherapy, vol. 72, no. 9, 2023, pp. 2949-2960, https://doi.org/10.1007/s00262-023-03466-8.